Maxime Dely: The Vital Role of Plasma-Derived Clotting Factors in Rare Disease Care
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Clotting factors: when plasma becomes a life-saving medicine
Plasma-derived medicinal products (PDMPs), such as factor VIII or IX concentrates, remain essential for patients living with rare and severe bleeding disorders
Conditions treated:
- Hemophilia A and B (factor VIII or IX deficiency)
- Rare congenital deficiencies (factor V, XI, XIII, protein S, plasminogen…)
- Severe coagulation disorders linked to liver disease, trauma, or critical care situations
Across the world, millions of patients rely every year on plasma-derived medicines when recombinant alternatives are not yet available, effective, or well tolerated.
In many cases, these treatments are the only therapeutic option capable of preventing life-threatening bleeding and enabling a normal quality of life.
Behind every vial of medicine lies a plasma donation — transformed into treatment, hope, and survival for patients facing rare diseases.
How can we raise greater awareness of the vital role that plasma-derived coagulation factors play in rare disease care and innovation?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome